Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 2
1994 5
1995 11
1996 16
1997 14
1998 11
1999 16
2000 19
2001 42
2002 71
2003 78
2004 132
2005 136
2006 154
2007 161
2008 209
2009 208
2010 184
2011 206
2012 201
2013 214
2014 221
2015 202
2016 169
2017 217
2018 218
2019 230
2020 265
2021 37
Text availability
Article attribute
Article type
Publication date

Search Results

3,220 results
Results by year
Filters applied: . Clear all
Page 1
Alemtuzumab for the treatment of multiple sclerosis.
Evan JR, Bozkurt SB, Thomas NC, Bagnato F. Evan JR, et al. Expert Opin Biol Ther. 2018 Mar;18(3):323-334. doi: 10.1080/14712598.2018.1425388. Expert Opin Biol Ther. 2018. PMID: 29309202 Review.
Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. ...Expert opinion: Alemtuzumab is highly efficacious; more so than first line treatments but comparable to natalizumab. ...
Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. ...Expert opinion:
Alemtuzumab as Treatment for Multiple Sclerosis.
Katsavos S, Coles A. Katsavos S, et al. Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):a032029. doi: 10.1101/cshperspect.a032029. Cold Spring Harb Perspect Med. 2018. PMID: 29500306 Free PMC article. Review.
One phase 2 and two phase 3 trials of this lymphocyte-depleting agent have established alemtuzumab's superior efficacy to interferon beta-1a over the short term (2-3 years) with greater relapse rate reduction, reduced accumulation of disability, and more frequent su …
One phase 2 and two phase 3 trials of this lymphocyte-depleting agent have established alemtuzumab's superior efficacy to inte …
[Alemtuzumab therapy 2017].
Biernacki T , Bencsik K , Sandi D , Vécsei L . Biernacki T , et al. Ideggyogy Sz. 2017 Nov 30;70(11-12):371-380. doi: 10.18071/isz.70.0371. Ideggyogy Sz. 2017. PMID: 29870645 Review. Hungarian.
The efficacy of alemtuzumab was proven in two phase III trials (CARE-MS I, II), where it was compared to subcutaneous interferon b-1a, administered three times weekly. In both studies alemtuzumab was superior to subcutaneous interferon b-1a in terms of relapse rate …
The efficacy of alemtuzumab was proven in two phase III trials (CARE-MS I, II), where it was compared to subcutaneous interferon b-1a …
Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
Li Z, Richards S, Surks HK, Jacobs A, Panzara MA. Li Z, et al. Clin Exp Immunol. 2018 Dec;194(3):295-314. doi: 10.1111/cei.13208. Epub 2018 Oct 1. Clin Exp Immunol. 2018. PMID: 30144037 Free PMC article. Clinical Trial.
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for treatment of relapsing multiple sclerosis (MS). ...The presence of anti-alemtuzumab antibody appeared to be associated with slower clearance of alemtuzumab from the circulation but had no
Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for treatment of relapsing multiple sclerosis (MS). ...The presen
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Esfahani K, et al. N Engl J Med. 2019 Jun 13;380(24):2375-2376. doi: 10.1056/NEJMc1903064. N Engl J Med. 2019. PMID: 31189042 No abstract available.
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.
Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK. Berger T, et al. CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. CNS Drugs. 2017. PMID: 27882532 Free PMC article. Review.
Alemtuzumab (Lemtrada) is a humanized monoclonal antibody approved in more than 50 countries. ...Given these considerations, it is beneficial to gain insight into how alemtuzumab is being used in the real-world clinical setting. Here, we report recommendations from
Alemtuzumab (Lemtrada) is a humanized monoclonal antibody approved in more than 50 countries. ...Given these considerations, it is be
Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.
Scappaticcio L, Castellana M, Virili C, Bellastella G, Centanni M, Cannavò S, Campennì A, Ruggeri RM, Giovanella L, Trimboli P. Scappaticcio L, et al. J Endocrinol Invest. 2020 Feb;43(2):219-229. doi: 10.1007/s40618-019-01105-7. Epub 2019 Aug 26. J Endocrinol Invest. 2020. PMID: 31452116
PURPOSE: Autoimmune thyroid events (ATEs) are common side effects after alemtuzumab (ALZ) therapy in patients with multiple sclerosis (MS). Our purpose was to reach more robust evidence on prevalence and outcome of the spectrum of alemtuzumab-induced autoimmune thyr …
PURPOSE: Autoimmune thyroid events (ATEs) are common side effects after alemtuzumab (ALZ) therapy in patients with multiple sclerosis …
A case of anaphylaxis to alemtuzumab.
Nye CJS, Wagner A, Kousin-Ezewu O, Jones JL, Coles AJ. Nye CJS, et al. J Neurol. 2019 Mar;266(3):780-781. doi: 10.1007/s00415-019-09214-2. Epub 2019 Feb 4. J Neurol. 2019. PMID: 30715557 No abstract available.
Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: A review.
Guilcher GMT, Shah R, Shenoy S. Guilcher GMT, et al. Pediatr Transplant. 2018 Mar;22(2). doi: 10.1111/petr.13142. Epub 2018 Jan 19. Pediatr Transplant. 2018. PMID: 29352515 Review.
Alemtuzumab is a humanized mAb targeted to CD52. Alemtuzumab is highly immunosuppressive with the ability to deplete T and B cells (in addition to other immune cell lines). A growing understanding of the PKs, dosing, and timing of administration of alemtuzumab
Alemtuzumab is a humanized mAb targeted to CD52. Alemtuzumab is highly immunosuppressive with the ability to deplete T and B c
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J, Shi S, Zhang Y, Luo J, Xiao Y, Meng L, Yang X. Zhang J, et al. Cochrane Database Syst Rev. 2017 Nov 27;11(11):CD010968. doi: 10.1002/14651858.CD010968.pub2. Cochrane Database Syst Rev. 2017. PMID: 29178444 Free PMC article. Review.
OBJECTIVES: To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of people with RRMS to prevent disease activity. ...MAIN RESULTS: We included three trials involving 1694 participants. All trials compared alemtuzumab
OBJECTIVES: To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of people with …
3,220 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page